PT - JOURNAL ARTICLE AU - Asano, Yuta AU - Veatch, Joshua AU - McAfee, Megan AU - Bakhtiari, Jakob AU - Lee, Bo AU - Martin, Lauren AU - Zhang, Shihong AU - Mazziotta, Francesco AU - Paulson, Kelly G. AU - Schmitt, Thomas M. AU - Munkbhat, Ariunnaa AU - Young, Cecilia AU - Seaton, Brandon AU - Hunter, Daniel AU - Horst, Nick AU - Lindberg, Marcus AU - Miller, Natalie AU - Stone, Matt AU - Bielas, Jason AU - Koelle, David AU - Voillet, Valentin AU - Gottardo, Raphael AU - Gooley, Ted AU - Oda, Shannon AU - Greenberg, Philip D. AU - Nghiem, Paul AU - Chapuis, Aude G. TI - Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma AID - 10.1101/2024.07.01.24309780 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.01.24309780 4099 - http://medrxiv.org/content/early/2024/07/05/2024.07.01.24309780.short 4100 - http://medrxiv.org/content/early/2024/07/05/2024.07.01.24309780.full AB - Although immune check-point inhibitors (CPIs) revolutionized treatment of Merkel cell carcinoma (MCC), patients with CPI-refractory MCC lack effective therapy. More than 80% of MCC express T-antigens encoded by Merkel cell polyomavirus, which is an ideal target for T-cell receptor (TCR)-based immunotherapy. However, MCC often repress HLA expression, requiring additional strategies to reverse the downregulation for allowing T cells to recognize their targets. We identified TCRMCC1 that recognizes a T-antigen epitope restricted to human leukocyte antigen (HLA)-A*02:01. Seven CPI-refractory metastatic MCC patients received CD4 and CD8 T cells transduced with TCRMCC1 (TTCR-MCC1) preceded either by lymphodepleting chemotherapy or an HLA-upregulating regimen (single-fraction radiation therapy (SFRT) or systemic interferon gamma (IFNγ)) with concurrent avelumab. Two patients who received preceding SFRT and IFNγ respectively experienced tumor regression. One experienced regression of 13/14 subcutaneous lesions with 1 ‘escape’ lesion and the other had delayed tumor regression in all lesions after initial progression. Although TTCR-MCC1 cells with an activated phenotype infiltrated tumors including the ‘escape’ lesion, all progressing lesions transcriptionally lacked HLA expression. While SFRT/IFNγ did not immediately upregulate tumor HLA expression, a secondary endogenous antigen-specific T cell infiltrate was detected in one of the regressing tumors and associated with HLA upregulation, indicating in situ immune responses have the potential to reverse HLA downregulation. Indeed, supplying a strong co-stimulatory signal via a CD200R-CD28 switch receptor allows TTCR-MCC1 cells to control HLA-downregulated MCC cells in a xenograft mouse model, upregulating HLA expression. Our results demonstrate the potential of TCR gene therapy for metastatic MCC and propose a next strategy for overcoming epigenetic downregulation of HLA in MCC.Competing Interest StatementM. McAfee, P. Nghiem, T. Schmitt and A. G. Chapuis are inventors on Fred Hutchinson patents related to the MCPyV TCR (patent no. 17-085-US-PCT) used in these studies. A. G. Chapuis received research funding through cooperative research and development agreements with bluebird Bio and Affini-T Therapeutics.Clinical TrialNCT03747484Funding StatementThis research was supported by NIH P01 grant (grant ID: P01CA225517), Bluebird Bio and Affini-T Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the FHCC Institutional Review Board, the US Food and Drug Administration, and registered at clinicaltrials.org as NCT03747484. All patients provided a written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors